Kansas City Kansas Community College

Cancer continues to be a major cause of death, with an anticipated 2,114,850 new cases and almost 626,140 deaths from the disease in 2026 [...].

COVID-19, caused by the new type of coronavirus SARS-CoV-2, has put an unprecedented impact on health, economy and social areas around the globe. It created an urgent global need for rapid diagnostics, effective therapeutics, and scalable vaccine manufacturing. The biomanufacturing industry played a central role in meeting this challenge by accelerating the development, production, and distribution of SARS‑CoV‑2 diagnostic assays and vaccines. This review provides an integrated overview of SARS‑CoV‑2 biology, clinical manifestations, transmission mechanisms, and major viral variants, followed by a detailed examination of diagnostic technologies. We further highlight the transformative impact of mRNA vaccine technologies, emphasizing advances in lipid nanoparticle formulation, large‑scale manufacturing, and regulatory‑aligned production strategies. The review also discusses the biomanufacturing sector’s rapid mobilization to overcome supply‑chain constraints, workforce shortages, and unprecedented global demand. Collectively, this work underscores how scientific innovation, industrial agility, and cross‑sector collaboration enabled the rapid deployment of diagnostics and vaccines that were essential to controlling the COVID‑19 pandemic.

Epilepsy is one of the most prevalent and serious brain disorders and affects over 70 million people globally. Antiseizure medications (ASMs) relieve symptoms and prevent the occurrence of future seizures in epileptic patients but have a limited effect on epileptogenesis. Addressing the multifaceted nature of epileptogenesis and its association with the Nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated neuroinflammation requires a comprehensive understanding of the underlying mechanisms of these medications for the development of targeted therapeutic strategies beyond conventional antiseizure treatments. Several types of NLRP3 inhibitors have been developed and their effect has been validated both in in vitro and in vivo models of epileptogenesis. In this review, we discuss the advances in understanding the regulatory mechanisms of NLRP3 activation as well as progress made, and challenges faced in the development of NLRP3 inhibitors for the treatment of epilepsy.

Objective: To describe experience of teaching research skills to the undergraduate bioscience students through COVID-19 studies.Methodology: Undergraduate students taking physiology, microbiology or biomanufacturing at a public college in Kansas City Kansas, during spring 2020 to fall 2023 were encouraged and mentored to 1) do literature survey on COVID-19 2) read the COVID-19 related clinical case study 3) read the COVID-19 related review article 4) learn basic bioinformatics tools 4) prepare and present poster in scientific conference 5) prepare review article.Results: This exercise allowed the students to learn using search engines like PubMed to find reliable information about the disease such as COVID-19. In the fall semester of 2020, students prepared a research paper about the coronavirus, COVID-19 disease, its symptoms and transmission. In the fall semester of 2022, students performed literature survey using PubMed, prepare presentations on various aspects of COVID-19 and wrote a review article. Students read review article about COVID-19 in the Spring semester of 2023 and responded to the questions related to the article. In the fall of 2021, students learned about the clinical aspects of COVID-19 by reading a clinical case study. This also helped students to understand molecular techniques like polymerase chain reaction (PCR), serology tests and how they are used to diagnose the disease. Similarly, in spring of 2022 students learned using NCBI tools to find the genomic and protein sequence of SARS-CoV-2 and its spike protein respectively. They also learned to design primers for PCR for the detection of coronavirus. Finally, students prepared and presented the poster on COVID-19 in a scientific conference.Conclusion: The methodology adopted enabled training the students to learn many research skills like literature survey, write review article, thoroughly read articles, understand the mechanism behind PCR, learn basic bioinformatics, prepare research poster and give scientific presentations. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

IntroductionColon cancer impacts the lives of Kansans and those across the United States. Epidermal growth factor receptor (EGFR) inhibitors, such as panitumumab and cetuximab, have gained popularity as first-line treatment for stage 4 colon cancer despite their toxicities and have been used by clinicians in later lines of therapy. EGFR inhibitors have been proven to be an efficacious first-line treatment for stage 4 colon cancer, but no study has investigated outcomes comparing EGFR inhibitors as first-line treatment to its use as second- or third-line treatment. This study investigated EGFR inhibitor therapy estimated overall survival when used as first-, second-, and third-line treatment for stage 4 colon cancer.MethodsA retrospective review was done for patients with stage 4 colon cancer who underwent EGFR inhibitor treatment at a large academic center from November 2007 to August 2021. The patients were stratified into five groups by the line in which they received the EGFR inhibitor treatment. A log-rank test was used to analyze the groups, and the median survival for each group was determined.ResultsA total of 68 patients were reviewed; 18 received first-line, 23 received second-line, 18 received third-line, 6 received fourth-line, and 3 received sixth-line treatment with an EGFR inhibitor. Fourth- and sixth-line therapies were excluded due to small patient size. There was no significant difference in estimated survival time between any of the lines. Median survival of the therapies was found.ConclusionsThere was no statistical difference in survival between the first-, second-, or third-line groups, which may provide justification for its use as a second- or third-line therapy.

Background: Phase 3 COMET trial (NCT02782741) compares avalglucosidase alfa (n=51) with alglucosidase alfa (n=49) in treatment-naïve LOPD. Methods: Primary objective: determine avalglucosidase alfa effect on respiratory muscle function. Secondary/other objectives include: avalglucosidase alfa effect on functional endurance, inspiratory/expiratory muscle strength, lower/upper extremity muscle strength, motor function, health-related quality of life, safety. Results: At Week 49, change (LSmean±SE) from baseline in upright forced vital capacity %predicted was greater with avalglucosidase alfa (2.89%±0.88%) versus alglucosidase alfa (0.46%±0.93%)(absolute difference+2.43%). The primary objective, achieving statistical non-inferiority (p=0.0074), was met. Superiority testing was borderline significant (p=0.0626). Week 49 change from baseline in 6-minute walk test was 30.01-meters greater for avalglucosidase alfa (32.21±9.93m) versus alglucosidase alfa (2.19±10.40m). Positive results for avalglucosidase alfa were seen for all secondary/other efficacy endpoints. Treatment-emergent adverse events (AEs) occurred in 86.3% of avalglucosidase alfa-treated and 91.8% of alglucosidase alfa-treated participants. Five participants withdrew, 4 for AEs, all on alglucosidase alfa. Serious AEs occurred in 8 avalglucosidase alfa-treated and 12 alglucosidase alfa-treated participants. IgG antidrug antibody responses were similar in both. High titers and neutralizing antibodies were more common for alglucosidase alfa. Conclusions: Results demonstrate improvements in clinically meaningful outcome measures and a more favorable safety profile with avalglucosidase alfa versus alglucosidase alfa. Funding: Sanofi Genzyme